Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.

Related Keywords

Melbourne ,Victoria ,Australia ,Jayesh Desai ,Clinical Research ,University Of Melbourne ,Phasei Early Drug Development Program ,Peter Maccallum Cancer Centre ,Sir Peter Maccallum Department Of Oncology ,Early Drug Development Program ,Sir Peter Maccallum Department ,Colorectal Cancer ,Onclive Tv ,